These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 7996809

  • 1. Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis.
    Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G.
    Kidney Int; 1994 Sep; 46(3):869-76. PubMed ID: 7996809
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis.
    Cvetkovic JT, Wållberg-Jonsson S, Ahmed E, Rantapää-Dahlqvist S, Lefvert AK.
    Rheumatology (Oxford); 2002 Sep; 41(9):988-95. PubMed ID: 12209031
    [Abstract] [Full Text] [Related]

  • 5. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM.
    Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G.
    Diabetes; 1995 Jan; 44(1):60-6. PubMed ID: 7813815
    [Abstract] [Full Text] [Related]

  • 6. Circulating antibodies recognizing malondialdehyde-modified proteins in healthy subjects.
    Vay D, Parodi M, Rolla R, Mottaran E, Vidali M, Bellomo G, Albano E.
    Free Radic Biol Med; 2001 Feb 01; 30(3):277-86. PubMed ID: 11165874
    [Abstract] [Full Text] [Related]

  • 7. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease.
    Boullier A, Hamon M, Walters-Laporte E, Martin-Nizart F, Mackereel R, Fruchart JC, Bertrand M, Duriez P.
    Clin Chim Acta; 1995 Jun 30; 238(1):1-10. PubMed ID: 7554289
    [Abstract] [Full Text] [Related]

  • 8. Oxidized LDL to autoantibodies against oxLDL ratio - the new biomarker associated with carotid atherosclerosis and cardiovascular complications in dialyzed patients.
    Pawlak K, Mysliwiec M, Pawlak D.
    Atherosclerosis; 2012 Sep 30; 224(1):252-7. PubMed ID: 22840691
    [Abstract] [Full Text] [Related]

  • 9. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis.
    Turk Z, Mrzljak V, Turk N, Metelko Z.
    Diabetes Nutr Metab; 1999 Dec 30; 12(6):413-7. PubMed ID: 10782563
    [Abstract] [Full Text] [Related]

  • 10. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis?
    Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G.
    Kidney Int; 1994 Mar 30; 45(3):876-83. PubMed ID: 8196291
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies.
    Virella G, Koskinen S, Krings G, Onorato JM, Thorpe SR, Lopes-Virella M.
    Clin Immunol; 2000 May 30; 95(2):135-44. PubMed ID: 10779407
    [Abstract] [Full Text] [Related]

  • 13. Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts.
    Kummu O, Turunen SP, Prus P, Lehtimäki J, Veneskoski M, Wang C, Hörkkö S.
    Immunology; 2014 Mar 30; 141(3):416-30. PubMed ID: 24168430
    [Abstract] [Full Text] [Related]

  • 14. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J, Santos F, Grosso D, Lima R, Barreira AL, Leite M, Mafra D, Abdalla DS.
    Nephron Clin Pract; 2008 Mar 30; 108(4):c298-304. PubMed ID: 18434752
    [Abstract] [Full Text] [Related]

  • 15. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
    Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, VADT Group of Investigators.
    J Diabetes Complications; 2016 Mar 30; 30(4):693-9. PubMed ID: 26861948
    [Abstract] [Full Text] [Related]

  • 16. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins.
    Slot MC, Theunissen R, van Paassen P, Damoiseaux JG, Tervaert JW, Limburg Nephrology Working Group.
    Clin Exp Immunol; 2007 Aug 30; 149(2):257-64. PubMed ID: 17521320
    [Abstract] [Full Text] [Related]

  • 17. Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke: a nested case-control study.
    Ahmed E, Trifunovic J, Stegmayr B, Hallmans G, Lefvert AK.
    Stroke; 1999 Dec 30; 30(12):2541-6. PubMed ID: 10582975
    [Abstract] [Full Text] [Related]

  • 18. Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events.
    George J, Aron A, Levy Y, Gilburd B, Ben-David A, Renaudineau Y, Zonana-Nachach A, Youinou P, Harats D, Shoenfeld Y.
    Hum Antibodies; 1999 Dec 30; 9(2):125-31. PubMed ID: 10405833
    [Abstract] [Full Text] [Related]

  • 19. Low-density lipoprotein oxidation and antioxidized LDL antibodies in peritoneal dialysis patients.
    Bellazzi R, Maggi E, Bellomo G, Finardi G, Gazo A, Nai M, Romanini D, Falaschi F, Frattoni A, Perani G.
    Adv Perit Dial; 1993 Dec 30; 9():312-7. PubMed ID: 8105953
    [Abstract] [Full Text] [Related]

  • 20. Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect.
    Johnston TP, Zhou X.
    J Cardiovasc Pharmacol; 2007 Apr 30; 49(4):246-52. PubMed ID: 17438410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.